Company: UHS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0000950170-25-027785
Chunk: 340

Company: UNIVERSAL HEALTH SERVICES INC
Filing Date: 2025-02-26
Form: 10-K
Item: Item 7
Chunk 340
---
4:

The $911 million of net cash used in investing activities during 2024 consisted of:

•$944 million spent on capital expenditures including capital expenditures for equipment, renovations and new projects at various existing facilities;

•$39 million of proceeds received from sales of assets and businesses;

•$19 million spent on the acquisition of businesses and property, and;

•$13 million received in connection with net cash inflows from forward exchange contracts that hedge our investment in the U.K. against movements in exchange rates;

2023:

The $763 million of net cash used in investing activities during 2023 consisted of:

•$743 million spent on capital expenditures including capital expenditures for equipment, renovations and new projects at various existing facilities;

•$41 million paid in connection with net cash outflows from forward exchange contracts that hedge our investment in the U.K. against movements in exchange rates;

•$24 million of proceeds received from sales of assets and businesses, and;

•$4 million spent on the acquisition of businesses and property. 

Net cash used in financing activities

Net cash used in financing activities was $1.145 billion during 2024 and $494 million during 2023.

2024:

The $1.145 billion of net cash used in financing activities during 2024 consisted of the following:

•spent $2.640 billion on net repayments of debt as follows: (i) $2.259 billion related to our previous tranche A term loan facility which was extinguished in September, 2024, and replaced with a new $1.2 billion tranche A term loan facility; (ii) $366 million related to our revolving credit facility, and; (iii) $15 million related to other debt facilities;

•generated $2.210 billion of proceeds from additional borrowings as follows: (i) $1.200 billion related to our new tranche A term loan facility, as mentioned above; (ii) generated approximately $500 million of net proceeds (before expenses) related to the public offering, in September, 2024, of 4.625% senior secured notes due in 2029; (iii) generated approximately $498 million of net proceeds (before expenses) related to the public offering, in September, 2024, of 5.050% senior secured notes due in 2034, and; (iv) $12 million of proceeds related to other debt facilities;

•spent $671 million to repurchase shares of our Class B Common Stock in connection